Treatment of Tinea Cruris

Introduction to Treatment Options

• The American Academy of Pediatrics recommends terbinafine 1% cream applied once daily for 1 week as the first-line treatment for tinea cruris in patients ≥12 years old, achieving approximately 94% mycological cure 1, 2
• Terbinafine 1% cream demonstrates superior mycological cure rates (94%) with a significantly shorter treatment duration (1 week once daily) compared to clotrimazole (4 weeks twice daily) 1, 2

Treatment Efficacy Comparison

• Clotrimazole 1% cream requires twice-daily application for 4 weeks, making it less convenient and potentially affecting compliance, with lower cure rates compared to terbinafine 1, 2
• Oral itraconazole (100 mg daily for 2 weeks or 200 mg daily for 1 week) is effective in adults and superior to oral griseofulvin 1, 2

Critical Treatment Endpoints

• The treatment endpoint must be mycological cure (negative microscopy and culture), not just clinical improvement, as clinical appearance may improve while infection persists 3

Safety Considerations

• Oral terbinafine is generally well tolerated, but monitor for occasional isolated neutropenia and rare liver failure, particularly in patients with preexisting liver disease 2
• Oral terbinafine is contraindicated in active or chronic liver disease, lupus erythematosus, and porphyria 3

Prevention of Recurrence and Transmission

• Patient education on covering active tinea pedis lesions with socks before wearing underwear, completely drying the crural folds after bathing, and avoiding skin-to-skin contact with infected individuals can help prevent autoinoculation and transmission 1, 2, 3